What happened

David Cameron has appealed for new Alzheimer's treatments to be made available through the NHS, drawing on his family's experience of his mother's illness. In a Telegraph interview reported by other outlets, he described Mary Cameron's distress and requests to his sister to end her life. She died in 2025.S1S2

Cameron, president of Alzheimer's Research UK, also called for a maximum 18-week wait for a dementia diagnosis. He argued that emerging treatments make this an appropriate time for government action. The appeal combines access to medicines with the capacity to identify people who might benefit from them.S2S3

Why it matters

A licence and an NHS access decision are separate steps. The medicines regulator, the MHRA, licensed lecanemab in August 2024 and donanemab that October. The Department of Health and Social Care says NICE independently assesses the costs and benefits when deciding recommendations for routine NHS use.R1R2S2

NICE's live project records give a more specific position than simply saying the drugs are being assessed. Notes dated 29 July for lecanemab and 30 July for donanemab say evaluation was paused because the companies and NHS England had begun commercial discussions. Both pages give the expected publication date as unconfirmed.R3R4

The licences do not cover everyone with dementia. Both concern adults with early Alzheimer's who have one or no copies of the ApoE4 gene. The MHRA describes evidence of slower disease progression, alongside risks including brain swelling or bleeding; patients with two copies had a less favourable balance of benefit and risk.R1R2

The background

Alzheimer's Research UK has proposed a dedicated Dementia Drugs Fund to provide carefully managed access while evidence is gathered. The charity says this should involve additional investment rather than taking money from existing dementia services. It is an advocacy proposal, not an announced NHS entitlement.R5

Cameron also expressed regret that his government had not introduced a cap on care costs. He suggested exploring an insurance-based approach, with government support, to protect families facing exceptionally high bills. He acknowledged that he did not have a complete answer, rather than presenting a finished funding scheme.S2S3

What happens next

Separate research is under way through AD-SMART, which tests several potential treatments within one study and can stop unsuccessful options or add new ones. Alzheimer's Research UK says this could shorten development time. It cautions that even positive results would still need regulatory and health-body review before treatments became routine care.R6

The government says it is investing £33m through the Dame Barbara Windsor Dementia Goals programme to increase recruitment into treatment studies. That research commitment does not specify when routine access to the two licensed medicines will begin. NICE's publication dates remain unconfirmed.S3R3R4